Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: A systematic review

Journal of Thoracic Disease

Volumn 9, Issue 7, 2017, Pages 2093-2101

  D'Ambrosio, Lia ^a,b   Centis, Rosella ^a   Tiberi, Simon ^c   Tadolini, Marina ^d   Dalcolmo, Margareth ^e   Rendon, Adrian ^f   Esposito, Susanna ^g   Migliori, Giovanni Battista ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b Public Health Consulting Group SAGL   (Switzerland)

^c ROYAL LONDON HOSPITAL   (United Kingdom)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e INSTITUTO OSWALDO CRUZ   (Brazil)

^f HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

^g UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Bedaquiline; Children; Delamanid; Extensively drug resistant tuberculosis (XDR TB); Multidrug resistant tuberculosis (MDR TB)

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; BEDAQUILINE; CAPREOMYCIN; CLOFAZIMINE; CYCLOSERINE; DELAMANID; ETHIONAMIDE; IMIPENEM; ISONIAZID; KANAMYCIN; LINEZOLID; PRETOMANID; PYRAZINAMIDE; QUINOLONE DERIVATIVE; RIFAMPICIN;

DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ELECTROLYTE DISTURBANCE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; KIDNEY DYSFUNCTION; LUNG TUBERCULOSIS; MULTIDRUG RESISTANT TUBERCULOSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QT PROLONGATION; REVIEW; SPUTUM CULTURE; SPUTUM SMEAR; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 85026444646     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.21037/jtd.2017.06.16     Document Type: Review

References (47)

1. World Health Organization. Global tuberculosis report 2016 WHO/HTM/TB/2016.13. Geneva: World Health Organization, 2016
2. Tiberi S, D'Ambrosio L, De Lorenzo S, et al. Tuberculosis elimination, patients' lives and rational use of new drugs: revisited. Eur Respir J 2016;47:664-7
3. Falzon D, Gandhi N, Migliori GB, et al. Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. Resistance to fluoroquinolones and secondline injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013;42:156-68
4. Migliori GB, Sotgiu G, Gandhi NR, et al. Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. Drug resistance beyond extensively drugresistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013;42:169-79
5. Diel R, Rutz S, Castell S, et al. Tuberculosis: cost of illness in Germany. Eur Respir J 2012;40:143-51
6. Diel R, Vandeputte J, de Vries G, et al. Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation. Eur Respir J 2014;43:554-65
7. World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis 2016 update. WHO/HTM/ TB 2016.04 Geneva: World Health Organization, 2016
8. Migliori GB, G De Iaco, G Besozzi, et al. First tuberculosis cases in Italy resistant to all tested drugs. Euro Surveill 2007;12:E070517.1
9. Caminero JA, Scardigli A. Classification of antituberculosis drugs: a new proposal based on the most recent evidence. Eur Respir J 2015;46:887-93
10. Sotgiu G, Tiberi S, D'Ambrosio L, et al for the International Carbapenem Study Group. Faster for less, the new 'Shorter' regimen for multidrug-resistant tuberculosis. Eur Respir J 2016;48:1503-7
11. Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drugresistant tuberculosis: 2011 update. Eur Respir J 2011;38:516-28
12. Tiberi S, Scardigli A, Centis R, et al. Classifying new anti-TB drugs: rationale and future perspectives. Int J Infect Dis 2017;56:181-4
13. Sotgiu G, Pontali E, Centis R, et al. New anti-tuberculosis drugs for special populations: a difficult-to-address issue. Eur Respir J 2016;48:957-8
14. World Health Organization. The use of delamanid in the treatment of multidrug-resistant tuberculosis. Interim policy guidance. WHO/HTM/TB2014.23. Geneva: World Health Organization, 2014
15. World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis. Interim policy guidance. WHO/HTM/TB/2013.6. Geneva: World Health Organization, 2013
16. World Health Organization. The use of delamanid in the treatment of multidrug-resistant tuberculosis in children and adolescents: interim policy guidance. WHO/HTM/ TB/2016.14. Geneva, World Health Organization, 2016
17. Harausz EP, Garcia-Prats A, Seddon JA, et al. on behalf of the Sentinel Project on Pediatric Drug-Resistant Tuberculosis. New Drugs, Repurposed Drugs, and Novel Regimens for Children with Multidrug-Resistant Tuberculosis: Practice-Based Recommendations. Am J Respir Crit Care Med 2016. [Epub ahead of print]
18. Pontali E, Sotgiu G, D'Ambrosio L, et al. Bedaquiline and MDR-TB: a systematic and critical analysis of the evidence. Eur Respir J 2016;47:394-402
19. Sotgiu G, Pontali E, Centis R, et al . Delamanid (OPC-67683) for treatment of multi-drug-resistant tuberculosis. Expert Rev Anti Infect Ther 2015;13:305-15
20. Tadolini M, Garcia-Prats AJ, D'Ambrosio L, et al. Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively-drug resistant tuberculosis: early experiences and challenges. Eur Respir J 2016;48:938-43
21. Esposito S, D'Ambrosio L, Tadolini M, et al. ERS/WHO Tuberculosis Consilium assistance with extensively drugresistant tuberculosis management in a child: case study of compassionate delamanid use. Eur Respir J 2014;44:811-5
22. Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality in multidrugresistant tuberculosis. Eur Respir J 2013;41:1393-400
23. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012;366:2151-60
24. Pym AS, Diacon AH, Tang SJ, et al. on behalf of the TMC207-C209 Study Group. Bedaquiline in the treatment of multi-and extensively drug-resistant tuberculosis. Eur Respir J 2016;47:564-74
25. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009;360:2397-405
26. Diacon AH, Pym A, Grobusch MP, et al. Multidrugresistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014;371:723-32
27. Dalcolmo M, Gayoso R, Sotgiu G, et al. Resistance profile of drugs composing the "shorter" regimen for multidrugresistant tuberculosis in Brazil, 2000-2015. Eur Respir J 2017;49(4)
28. Sotgiu G, Pontali E, Migliori GB. Linezolid to treat MDR-/XDR-Tuberculosis: available evidence and future scenarios. Eur Respir J 2015;45:25-9
29. Villar M, Sotgiu G, D'Ambrosio L, et al. Linezolid safety, tolerability and efficacy to treat multidrug-and extensively drug-resistant tuberculosis. Eur Respir J 2011;38:730-3
30. De Lorenzo S, Centis R, D'Ambrosio L, et al. On linezolid efficacy and tolerability. Eur Respir J 2012;39:770-2
31. Sotgiu G, Centis R, D'Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and metaanalysis. Eur Respir J 2012;40:1430-42
32. Sotgiu G, Centis R, D'Ambrosio L, et al; International Group for the study of Linezolid. Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence. Eur Respir J 2013;42:288-90
33. Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012;367:1508-18
34. Sotgiu G, Centis R, D'Ambrosio L, et al. Low minimal inhibitory concentrations of linezolid against multidrugresistant tuberculosis strains. Eur Respir J 2015;45:287-9
35. De Lorenzo S, Alffenaar JW, Sotgiu G, et al. Efficacy and safety of meropenem-clavulanate added to linezolidcontaining regimens in the treatment of MDR-/XDR-TB. Eur Respir J 2013;41:1386-92
36. Tiberi S, Payen MC, Sotgiu G, et al. Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of multidrug and extensively drug-resistant tuberculosis. Eur Respir J 2016;47:1235-43
37. Tiberi S, Sotgiu G, D'Ambrosio L, et al. Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis. Clin Infect Dis 2016;62:1188-90
38. Tiberi S, Sotgiu G, D'Ambrosio L, et al. Comparison of effectiveness and safety of imipenem/clavulanate-versus meropenem/clavulanate-containing regimens in the treatment of multidrug and extensively drug-resistant tuberculosis. Eur Respir J 2016;47:1758-66
39. Tiberi S, D'Ambrosio L, De Lorenzo S, et al. Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience. Eur Respir J 2016;47:333-6
40. Matteelli A, D'Ambrosio L, Centis R, et al. Compassionate and optimum use of new tuberculosis drugs. Lancet Infect Dis 2015;15:1131-2
41. Tadolini M, Lingtsang RD, Tiberi S, et al. First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline. Eur Respir J 2016;48:935-8
42. Tadolini M, Lingtsang RD, Tiberi S, et al. Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid, and clofazimine. Eur Respir J 2016;48:1527-9
43. Wallis RS. Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine. Eur Respir J 2016;48:1526-7
44. Moher D, Liberati A, Tetzlaff J, et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 2009;21;6:e1000097
45. ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Available online: www.clinicaltrials.gov (last access: January 2nd, 2017)
46. Esposito S, Bosis S, Tadolini M, et al. Efficacy, safety, and tolerability of a 24-month treatment regimen including delamanid in a child with extensively drug-resistant tuberculosis: A case report and review of the literature. Medicine (Baltimore) 2016;95:e5347
47. Borisov SE, Dheda K, Enwerem M, et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR-and XDR-TB: a multicentre study. Eur Respir J 2017;49(5)